The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Pitt
B
B
Williams
G
G
Remme
W
W
Martinez
F
F
Lopez-Sendon
J
J
Zannad
F
F
Neaton
J
J
Roniker
B
B
Hurley
S
S
Burns
D
D
Bittman
R
R
Kleiman
J
J
D000450:Aldosterone / Q000097:blood; D004311:Double-Blind Method; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D018401:Sample Size; D013148:Spironolactone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016019:Survival Analysis; D013599:Systole
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone